Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Authors: Ernst Rüdiger Kuse
Ploenchan Chetchotisakd
Clovis Arns da Cunha
Markus Ruhnke
Carlos Barrios
Digumarti Raghunadharao
Jagdev Singh Sekhon
Antonio Freire
Venkatasubramanian Ramasubramanian
Ignace Demeyer
Marcio Nucci
Amorn Leelarasamee
Frédérique Jacobs
Johan Decruyenaere
Didier Pittet
Andrew J. Ullmann
Luis Ostrosky-Zeichner
Olivier Lortholary
Sonja Koblinger
Heike Diekmann-Berndt
Oliver A. Cornely
Klinik für Viszeral- und Transplantationschirurgie
Khon Kaen University
R Desembargador Vieira Cavalcante
Charité – Universitätsmedizin Berlin
Pontificia Universidade Catolica do Rio Grande do Sul
Nizam's Institute of Medical Sciences
Dayanand Medical College and Hospital
Santa Casa de Belo Horizonte
Apollo Hospitals
Onze Lieve Vrouw Hospital
Universidade Federal do Rio de Janeiro
Mahidol University
Hospital Erasme
University Hospital of Ghent
Hopitaux universitaires de Geneve
Klinikum der Johannes-Gutenberg-Universitat und Fachbereich Medizin
University of Texas Medical School at Houston
Hopital Necker Enfants Malades
Astellas Pharma GmbH
Uniklinik Koln
Keywords: Medicine
Issue Date: 5-May-2007
Citation: Lancet. Vol.369, No.9572 (2007), 1519-1527
Abstract: Background: Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods: We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with, number NCT00106288. Findings: 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89·6%) patients treated with micafungin and 170 (89·5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0·7% (95% CI -5·3 to 6·7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events-including those that were serious or led to treatment discontinuation-with micafungin than there were with liposomal amphotericin B. Interpretation: Micafungin was as effective as-and caused fewer adverse events than-liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis. © 2007 Elsevier Ltd. All rights reserved.
ISSN: 01406736
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.